ABOUT REFORM BIOLOGICS

Our Vision

At ReForm, our vision is to improve the lives of fragile patients by optimizing the delivery of their essential biologic medicines. Fragile patients include children and the elderly, as well as those suffering from neurological conditions and other debilitating diseases. With easier delivery of vital treatments, patients can experience less disruption and less pain, facilitating overall better adherence to therapeutic guidelines with better outcomes.

Our Mission

Our mission is to improve biologic formulations by incorporating our proprietary, patented technology to enhance patients’ lives, particularly for fragile populations such as children and the elderly. We are doing this by improving the viscosity and stability of known biologics, for our own formulations as well as for those of other biopharmaceutical companies to make their medicines better tolerated by patients and more easily administered.

MANAGEMENT TEAM

Jeffrey S. Hackman - Chief Executive Officer

Jeffrey S. Hackman is President and Chief Executive Officer (CEO) of ReForm Biologics. Prior to joining ReForm, Jeff was President of US Operations for EUSA, a global pharmaceutical company focused on oncology and rare diseases. Previously, he had been acting CEO of Novelion Therapeutics, where he transformed the company to profitability. He joined Novelion from Shire Inc., where he had been Senior VP and Head of US Internal Medicine / Oncology Franchise. Previously, he established the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He has also held senior roles in several other pharmaceutical companies.

Neal I. Muni, MD, MSPH - Chief Operating Officer

Dr. Neal Muni is Executive Vice President and Chief Operating Officer (COO) of ReForm. Prior to joining ReForm, Dr. Muni most recently served as the CEO of Azurity Pharmaceuticals (formerly CutisPharma). During his tenure, Dr. Muni led the transformation of CutisPharma from pharmacy distribution into a fully integrated specialty pharma, leading the acquisition of Silvergate Pharmaceuticals as well as overseeing the FDA approval and launch of two pipeline drugs, FIRVANQ® for clostridium difficile colitis and Katerzia® for pediatric hypertension.

Prior to Azurity, Dr. Muni served as the Head of New Product Planning and Corporate Strategy at Sunovion Pharmaceuticals. Before that, Dr. Muni was an engagement manager at the healthcare investment bank Leerink Swann (now SVB Leerink). He was a Medical Officer in the Division of Cardiovascular Devices at the FDA before joining Leerink. Over the past 20 years, Dr. Muni has maintained staff appointments at Harvard Medical School and its teaching hospitals, including Brigham and Women’s Hospital, Dana Farber Cancer Institute, and Faulkner Hospital, as well as the Wyss Institute at Harvard University. He received his MD as well as MSPH from the Tulane School of Medicine, and a BA in Business Economics and B.Sc. in Biochemistry from Brown University.

Kevin P. Kavanaugh - Chief Financial Officer
Kevin P. Kavanaugh, CPA is Vice President and Chief Financial Officer (CFO) of ReForm Biologics. Kevin has over 25 years’ experience in the accounting field in both private and public settings. Mr. Kavanaugh has served as ReForm’s Controller since its founding. Previously, Mr. Kavanaugh was the Controller of Soane Labs, Transform Materials and Crop Enhancement where he engaged in multiple successful license and business agreements. Mr. Kavanaugh has also held management roles at Burst Media, State Street Bank and Iron Mountain, following several years in public accounting, including Ernst & Young.
Robert Mahoney, Ph.D. - Chief Scientific Officer

Dr. Mahoney has spent 25 years leading the development of disruptive new products and processes for industries including water treatment, oilfield technologies, pharmaceuticals, agriculture, and mineral processing. Before joining ReForm, he served as VP of R&D under David Soane at Soane Energy, leading to the successful deployment of an innovative self-suspending proppant technology. Prior to joining Dr. Soane, he was VP of R&D at Polymer Ventures, designing and commercializing many new specialty polymer products. Previously, Dr. Mahoney was responsible for development of next-generation performance additives at Nalco (now part of Ecolab), the global leader in water and process treatment chemicals. He received his Ph.D. in physical organic chemistry from the University of Colorado at Boulder and has authored numerous patents, publications, and presentations.

Sharon Webb, M.D., Ph.D., J.D. - VP of Intellectual Property
Dr. Webb has been helping companies and investors with IP strategies for over 20 years, focusing on investor-side diligence and company-side portfolio development and technology transfer. She has been managing intellectual property for the Soane family of companies since 2006. Before joining Dr. Soane, she was a partner at Goodwin Procter LLP in Boston, Massachusetts. Prior to entering the legal field, Dr. Webb was a board-certified surgeon, Fellow of the American College of Surgeons, with teaching positions at Harvard, Tufts and the University of Pennsylvania. She received her J.D. from Harvard, her Ph.D. from Yale, and her M.D. from Duke.

BOARD OF DIRECTORS

James Sherblom - Chairman

Dr. Jim Sherblom is an entrepreneur, social impact investor, spiritual seeker, and transcendentalist. Jim was a founder of the Massachusetts Biotechnology Council and served as its second President.  As Senior Vice President and Chief Financial Officer of Genzyme Corporation Jim led their initial public offering and helped create many of the early biotechnology industry’s most innovative financing structures.  As Chairman and CEO of Transgenic Sciences Inc. he led a ten-fold growth of this company over a period of five years.  As founding Managing Partner of Seaflower Ventures Jim has been involved as a founder, early investor, board member, or board chair of over a dozen early stage biotechnology, life science, and social impact companies over the last three decades.  Jim currently serves as the largest investor and CFO of GrainPro Inc. and also on the board of Connected Homecare Inc.  Jim holds a BA from Yale, an MBA from Harvard, and Master of Divinity and Doctor of Ministry degrees from Andover Newton Theological School.

Jeffrey S. Hackman
Jeffrey S. Hackman is President and Chief Executive Officer (CEO) of ReForm Biologics. Prior to joining ReForm, Jeff was President of US Operations for EUSA, a global pharmaceutical company focused on oncology and rare diseases. Previously, he had been acting CEO of Novelion Therapeutics, where he transformed the company to profitability. He joined Novelion from Shire Inc., where he had been Senior VP and Head of US Internal Medicine / Oncology Franchise. Previously, he established the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He has also held senior roles in several other pharmaceutical companies.
Roopom Bannerjee
Roopom Banerjee has over 25 years of experience in corporate strategy, investment banking, private equity, company formation and operating leadership. Roopom is currently the Managing Partner of WhiteLeaf Advisors, a Strategic Advisor to Bain Capital, and an Operating Partner at CRG Investments. Previously he was President and CEO of Raindance Technologies which pioneered the first liquid biopsy blood tests for noninvasive cancer detection, as well as a Director of Investment Banking at Leerink Swann, and a consultant at McKinsey. Roopom holds dual BS degrees in Biology and Economics from MIT, and an MPP from Harvard.
Kirsten Flowers
Kirsten Flowers brings more than 15 years of pharmaceutical and biotech experience and is currently the Chief Commercial Officer for Kura Oncology. She has previously served as SVP of Commercial Operations at Array Biopharma where she built and led the commercial organization that delivered the successful launch of Braftovi® + Mektovi® for patients with BRAF-mutant melanoma. Before joining Array, Kirsten held several leadership positions within Pfizer including the U.S. commercial lead for the launch of the blockbuster drugs IBRANCE® in breast cancer and INLYTA® in renal cell carcinoma. Kirsten earned her MBA from Harvard Business School, and her BS in Molecular & Cellular Biology and Psychology from the University of Arizona.
Zach Jonasson, Ph.D. - Co-founder
Dr. Jonasson has devoted 20 years to R&D, business development, and venture investment in life sciences companies. He is currently a partner at Phoenix Venture Partners (PVP), specializing in advanced materials companies. Prior to founding PVP, he was a general partner and Kauffman Fellow at Seaflower Ventures where his prior investments included Serenex (acquired), Metaworks (acquired), RCM Technologies (acquired), and Valeritas. In addition, he presently serves on several advisory boards, including the Commercialization Council for Oregon Nanoscience and Microtechnologies Institute (ONAMI), the Advisory Board for the Oregon Innovation Cluster, and the Advisory Board of the Life Sciences Institute at the University of British Columbia. Dr. Jonasson earned a BS from Georgetown University, and AM and PhD degrees from Harvard University.
Barbara K. Finck, MD

Dr. Finck is a board-certified rheumatologist with more than 25 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings. Dr. Finck, whose drug development activities have spanned multiple therapeutic areas, started her pharmaceutical career at ALZA as medical director for early clinical development of Ditropan-XL®, to treat spasms of the bladder. She subsequently held senior level positions at a half-dozen innovative biopharmaceutical companies. At Immunex (later acquired by Amgen) she was lead medical director for the Phase III clinical development of Enbrel® in rheumatoid arthritis and juvenile idiopathic arthritis. At Eos Biotechnology, she was VP for Clinical Development. In addition, she was on the executive teams at PDL Biopharma (VP, Clinical Development), Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer), and NKT Therapeutics, Inc. (Chief Medical Officer). In her role as the Chief Medical Officer at Coherus, she was instrumental in the development and approval of UDENYCA®, a biosimilar pegfilgrastim.

Stuart Randle
Stuart Randle has 30 years of biomedical experience including as Division President of Baxter Healthcare, President and CEO of ACT Medical, President and CEO of GI Dynamics, and most recently, President and CEO of Ivenix. He serves on the Board of Directors of Teleflex (TFX) and Beacon Roofing Supply (BECN) and was previously on the Boards of Flex Pharma (FLKS), Specialized Health Products International (SHPI), and GI Dynamics (GID). He was also an Entrepreneur-in-Residence for Advanced Technology Ventures, a healthcare and IT venture capital firm. Stuart holds a BS from Cornell and a Northwestern MBA.
Edward Sullivan
Edward is a comprehensive business strategist and financial expert with 35 years of experience advising public and private companies at all stages of development from early stage, pre-IPO businesses to multi-billion-dollar market cap public companies. Trusted counselor to multinational corporations in various industries adept at guiding businesses through years of growth and transformational change. Valued by boards, clients, and colleagues for honest feedback, a steadfast character, and collaborative leadership style. Edward holds a BS in Accounting from Bryant University.
V. Bryan Lawlis, Ph.D.
Dr. Lawlis is a leader in developing and commercializing biologic therapeutics. Besides his role on the ReForm Board of Directors, he currently serves as a director for BioMarin Pharmaceuticals, Inc., Coherus Biosciences, Geron Corporation, and several privately-held biotechnology companies. In addition, he is President, Chief Executive Officer and co-founder of Itero Biopharmaceuticals LLC. Prior to this, between 2001 and 2006, he served as COO, CEO, and President at Aradigm Corporation. Before joining Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, serving as its president, CEO, and chairman between 1996 and 2001. From 1981 to 1996, he was employed at Genencor Inc. and Genentech Inc., most recently as Vice President of Process Sciences. Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin and a Ph.D. in biochemistry from Washington State University.
John Yee, MD, MPH

Dr. John Yee is currently Chief Medical Officer at Sobi North America. Prior to joining Sobi, he served as Senior Vice President, Medical Affairs at Flexion Therapeutics, Senior Vice President and Global Head of Medical Affairs at Vertex Pharmaceuticals and Vice President, Medical Affairs, Safety and Operations at Intarcia Therapeutics. From 2011 to 2016, Dr. Yee was at AstraZeneca Pharmaceuticals, where he served as Vice President, US Head Medical Officer and Vice President and Head of Medical Affairs for the US Diabetes franchise. Dr. Yee began his industry career at Genzyme Corporation in 2003 as Director, Global Medical Programs and later served in other leadership roles, including Vice President, Global Medical Affairs and Vice President, Global Head, Evidence-Based Medicine and Health Outcomes Research. Dr. Yee earned his MD at Harvard Medical School and graduated from the T.H. Chan School of Public Health at Harvard with an MPH in Health Care Management. He completed his pediatric residency and fellowship training at Boston Children’s Hospital. Prior to joining industry, John held leadership roles at Boston Children’s Hospital and was a faculty member at Harvard Medical School.

ADVISORY BOARD

John M. Sorvillo Ph.D. - Chairman
Dr. Sorvillo joined ReForm as President & CEO in 2016 and during his tenure the company partnered with leading pharmaceutical companies to improve their formulations with ReForm’s excipients, and he led the company in advancing its understanding of protein-protein and protein-solvent interactions. Dr. Sorvillo has >30 years of biotech and pharma expertise with extensive experience in business development, strategic planning, project and alliance management, and technology transfer. Before joining ReForm, Dr. Sorvillo was Director of Business Development & Licensing at Amgen. In previous roles, he was responsible for business development for Genocea Biosciences, Altus Pharmaceuticals, and ArQule Inc. Previously, he headed the research division at OSI Pharmaceuticals, and he was CEO of Bionaut Pharmaceuticals. He earned a Ph.D. in Immunology from the NYU Medical Center and received postdoctoral training at Memorial Sloan Kettering Cancer Center.
John Carpenter Ph.D.
Dr. Carpenter is Professor of Pharmaceutical Sciences at the University of Colorado School of Pharmacy, and a Co-Founder and Co-Director of the University of Colorado Center for Pharmaceutical Biotechnology. His research interests include mechanisms for protein degradation and protein stabilization in pharmaceutical formulations during bioprocessing and delivery. He has published more than 230 peer-reviewed papers and is an inventor on 30 issued patents. Dr. Carpenter is Editor for Reviews and Commentaries for Journal of Pharmaceutical Sciences and serves on the Editorial Advisory Boards for Pharmaceutical Research, The AAPS Journal, Journal of Pharmaceutical Sciences, Current Pharmaceutical Biotechnology, Molecular Pharmaceutics, and BioPharm International. He is a Fellow of the American Association for Advancement of Science (AAAS) and the American Association of Pharmaceutical Scientists (AAPS) and has received the AAPS Research Achievement Award in Biotechnology. Dr. Carpenter holds a B.S. in biology from Duke University, a M.S. in zoology from Oregon State University, and a Ph.D. in biology from University of Southwest Louisiana.
Alan Herman, Ph.D.

Dr. Herman has over 35 years of experience in the life sciences sector and expert in protein characterization. He was most recently Chief Scientific Officer at Coherus Biosciences, a leading biopharmaceutical company developing safe, high-quality biosimilar therapeutics. Previously, he was Vice President of Product Development and CSO at Althea Technologies and President of WindRose Analytica, Inc. Dr. Herman worked a number of other biotech companies, including Genentech and Amgen. He has a Ph.D. in Protein Chemistry from Duke University.

Andrew Jones, D. Phil.
Dr. Jones, with over 35 years’ experience in biochemistry, protein chemistry, and biophysics, joins ReForm’s Scientific Advisory Board. Currently he also serves on the Scientific Advisory Boards of Coherus Biosciences and Versartis Inc. Most of his career, from 1981-2004, was spent at Genentech. Shortly after joining that company, he founded its Medical and Analytical Chemistry Department, serving as its Director from 1983 to 1987. Subsequently, he filled various R&D and management roles at the company through 1994. Since 2004, Dr. Jones has worked as a consultant to various biopharmaceutical companies, including a two-year term as the Head of the Scientific Advisory Board for Itero Biopharmaceuticals, from 2009 to 2011. Dr. Jones obtained his B.A. (Honors) degree in Biochemistry from St. John’s College, Oxford University. He received his D. Phil. degree in Biology from the University of York, and performed postdoctoral research at McMaster University and at Cornell University.
Mark Moody, Ph.D.
Dr. Moody has spent over 20 years in biopharmaceutical development including process/analytical development, formulation, manufacturing, toxicology, regulatory, and clinical development. Most recently, Dr. Moody was the Vice-President of Manufacturing at Merrimack Pharmaceuticals, Inc. where he worked for 13 years, helping to grow it from a three-person start-up to a mid-size biopharmaceutical company with eight products in clinical development. Previously, Dr. Moody was the Director of Research at Pierce Chemical Co., where he developed and commercialized protein array technology for the drug screening market. Prior to that, he served as the Director of Molecular Biology at EndoGen Inc. where he developed and commercialized mRNA quantification technology. Dr. Moody holds a B.S. in biology from Western Carolina University and a Ph.D. in microbiology from the University of Georgia.
Neil Schauer, Ph.D.
Dr. Schauer is an executive-level leader and scientist with over 25 years of experience in the development and manufacture of biologic therapeutics. Most recently, he was Senior VP of Technical Operations at Avaxia Biologics. Before that, he held the position of Vice President of Process Sciences at Inspiration Biopharmaceuticals. His past positions in the biopharmaceutical industry include Senior Director Global Biologics at Hospira, Director of Manufacturing Sciences at Biogen Idec, and program management positions at EMD Pharmaceuticals and Biogen Idec. He began his biopharmaceutical career at Genetics Institute (now part of Pfizer). In addition, Dr. Schauer directed the Technology Development and Downstream Product Development Groups at Millipore Corp. Dr. Schauer received his B.S. in Biochemistry and Biology and Ph.D. in Anaerobic Microbiology from Virginia Polytechnic Institute and State University, and received post-doctoral training at the University of Georgia.
Mary Szela
Mary Szela is Chief Executive Officer of TriSalus Life Sciences, a company focused on improving outcomes in patients with pancreatic and liver metastasis by combining immuno-oncology therapeutics with a novel technology to enable improved patient outcomes. Prior to joining TriSalus, she was of CEO of Novelion Therapeutics executed a merger with QLT. Prior to her role at Novelion, Szela served as CEO of Melinta Pharmaceuticals, where she transformed Melinta from a scientific organization to one prepared for the commercial launch of multiple antibiotic products with billion-dollar potential. Previously, Ms. Szela spent 25 years of progressive P&L leadership roles at Abbott Laboratories, where she was consistently a catalyst for profound and productive change. During her Abbott tenure, Mary held positions of senior leadership, including President of U.S. pharmaceuticals, a $9 billion dollar business.

Ms Szela has an M.B.A. from the University of Illinois at Chicago, US, and a B.S. Nursing degree from the University of Illinois at Chicago, US.